Targeting TL1A in Immune-Mediated Inflammatory Diseases: From an Inflammatory Amplifier to a New Strategy for Precision Intervention

Top Stories

HLX43: A Next-Generation PD-L1-Targeted ADC Breaking Traditional Limitations in Cancer Therapy

BCMA-Targeted ADC Therapy: A New Direction for Precision Treatment of Multiple Myeloma

Latest Coverage

From R&D to Accessibility: Innovative Medicines Empower the Upgrade of Global Health Systems
In the global health landscape, innovative medicines are playing a transformative role. From molecular discoveries in...

World’s First! In Vivo CAR-T Successfully Treats Systemic Lupus Erythematosus: A Revolutionary Breakthrough in Immune Reprogramming
World’s First! In Vivo CAR-T Successfully Treats Systemic Lupus Erythematosus: A Revolutionary Breakthrough in Immune...

China’s Innovative Drugs Going Global: What Does $57.1 Billion in BD Deals Mean?
Against the backdrop of a continuously evolving global pharmaceutical landscape, China’s innovative drug sector is ac...

RNA Therapeutics Trends: Commercial Breakthrough and Global Competitive Landscape in 2026
Since 2026, RNA therapeutics have continued to gain momentum, emerging as one of the most closely watched sectors in ...

mRNA-LNP Delivery Technology: Breaking Through the Tumor Microenvironment and Ushering in a New Era of Precision Immunotherapy
As a cutting-edge focus in oncology, mRNA-LNP (lipid nanoparticle) delivery technology has become a central highlight...

The Rise of Claudin18.2: Gastric Cancer Precision Therapy Enters an Accelerated Phase
The Rise of Claudin18.2 in Gastric Cancer

In-Depth Analysis

Targeting TL1A in Immune-Mediated Inflammatory Diseases: From an Inflammatory Amplifier to a New Strategy for Precision Intervention

HLX43: A Next-Generation PD-L1-Targeted ADC Breaking Traditional Limitations in Cancer Therapy

BCMA-Targeted ADC Therapy: A New Direction for Precision Treatment of Multiple Myeloma

From R&D to Accessibility: Innovative Medicines Empower the Upgrade of Global Health Systems